irinotecan/floxuridine (LY01616)
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 25, 2024
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=78 | Enrolling by invitation | Sponsor: Luye Pharma Group Ltd. | Trial completion date: Oct 2023 ➔ Oct 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024
Metastases • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
May 19, 2023
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=78 | Enrolling by invitation | Sponsor: Luye Pharma Group Ltd.
Metastases • New P1/2 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1